Cho SH, Kim KK. Obesity treatment in ambulatory care focused on pharmacotherapy. Korean J Fam Pract 2020;10:77-86. https://doi.org/10.21215/kjfp.2020.10.2.77

Karam JG, McFarlane SI. Secondary causes of obesity. Therapy 2007;4:641-50. https://doi.org/10.2217/14750708.4.5.641

Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-42. https://doi.org/10.1038/oby.2011.330

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52. Erratum in: Lancet 2011;377:1494. https://doi.org/10.1016/S0140-6736(11)60205-5

De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med 2019;17:169. https://doi.org/10.1186/s12967-019-1919-y

Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: endocrine work-up in obesity. Eur J Endocrinol 2020;182:G1-32. https://doi.org/10.1530/eje-19-0535